← Arvinas, Inc. (ARVN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Arvinas, Inc. (ARVN)
Pharmaceutical Preparations · market cap $536M · as of 2026-07-07
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Arvinas (ARVN) is a clinical-stage biotech pioneering PROTAC-based targeted protein degradation, with a market cap of ~$541M and a deeply concerning cash position of $87.3M representing roughly 3.8 months of runway. The pipeline spans four Phase 2 programs across breast cancer, metastatic prostate cancer, and KRAS G12D-mutant tumors, though the lead asset listed as 'Anastrozole' — a generic aromatase inhibitor — raises data-quality questions about how the pipeline is being characterized here.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
- 2026-11-30 (est.)Phase 2 · ARV-806imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ARV-471 | Phase 2 | Breast Cancer |
| ARV-110 | Phase 2 | Prostate Cancer Metastatic |
| ARV-806 | Phase 2 | KRAS G12D Mutation |
Price & technical context
3-month
-12.3%
6-month
-31.7%
12-month
-18.8%
52-wk range
$6.98–$13.83
vs 50-day MA
-14.0%
vs 200-day MA
-26.9%
Realized vol
54.3%
Max drawdown
-78.4%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ARVN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.